This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds,
such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines,
imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or
Formula II:
##STR1##
The invention is particularly related to such compounds that bind with high selectivity
and high affinity to the benzodiazepine site of GABAA receptors. This
invention also relates to pharmaceutical compositions comprising such compounds
and to the use of such compounds in treatment of certain central nervous system
(CNS) diseases. Processes for preparing compounds of Formula I and Formula II are disclosed.
This invention also relates to the use of benzimidazoles, pyridylimidazoles
and related bicyclic heteroaryl compounds of Formula I or Formula II in combination
with one or more other CNS agents to potentiate the effects of the other CNS agents.
Additionally this invention relates to the use such compounds as probes for the
localization of GABAA receptors in tissue sections.